drugset / Trial / NCT03156153

A Study of Bumetanide for the Treatment of Autism Spectrum Disorders

NCT03156153

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators are going to carry out a randomized double-blind placebo-controlled trial to study the efficiency and mechanism of bumetanide on the treatment of children with Autism Spectrum Disorder.

Timeline

Start
2017-05-24
Primary completion
2019-07-08
Completion
2019-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bumetanide Small molecule 0.5 mg Oral